Humacyte, Inc. (HUMA) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2022
Loading P/E history...
HUMA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Humacyte, Inc. (HUMA) trades at a price-to-earnings ratio of -0.9x, with a stock price of $1.08 and trailing twelve-month earnings per share of $-0.23.
The current P/E is 104% below its 5-year average of 19.7x. Over the past five years, HUMA's P/E has ranged from a low of 9.3x to a high of 30.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, HUMA trades at a 104% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, HUMA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HUMA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HUMA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 168.5 | - | +166%Best | |
| $222M | 31.2 | 2.43 | +48% | |
| $2B | 42.8 | 2.21 | +31% | |
| $56B | 26.3 | 1.59Best | -1% | |
| $84B | 29.2 | - | +55% | |
| $100B | 21.6Lowest | - | +31% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
HUMA Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $2.11 | $0.07 | 30.1x | +53% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $3.26 | $0.35 | 9.3x | -53% |
Average P/E for displayed period: 19.7x
See HUMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HUMA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HUMA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHUMA — Frequently Asked Questions
Quick answers to the most common questions about buying HUMA stock.
Is HUMA stock overvalued or undervalued?
HUMA trades at -0.9x P/E, below its 5-year average of 19.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does HUMA's valuation compare to peers?
Humacyte, Inc. P/E of -0.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is HUMA's PEG ratio?
HUMA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2022.